Recently, study discovered that AURKB is responsible for cancer resistance to chemical reagents such as cisplatin and paclitaxel [12], and it has been established as a potential target to overcome the acquired resistance to EGFR TKIs when patients do not harbor resistance mutations in the EGFR gene [13]. This evidence concerns the gene AURKB and cancer.